Skip to Content



March 20, 2012

Forming a global cancer network for research, clinical care, education and prevention.

Contact GAPConnect.


GAP Conference 2012 - Profiles of Norwegian Co-Chairs

As the time of the GAP Conference 2012 in May draws closer, we would like to highlight the researchers and research that are the impetus for the gathering. In this issue, we briefly profile six of the Norwegian co-chairs.

Jon Håvard Loge, M.D., Ph.D.  - Co-chair of the Cancer Survivorship keynote and workshop

Loge specializes in child and adolescent psychiatry and is a professor at the University of Oslo. His research concentrates on late effects of cancer on the patient, cancer survivorship, patient-reported outcomes and palliative medicine.

Åslaug Helland, M.D., Ph.D. - Co-chair of the Thoracic/Lung workshop

Helland is an oncologist and researcher at the Oslo University Hospital - Radium Hospital. She heads the lung cancer and translational research groups, which focuses on molecular characterization and other translational studies.

Ola Myklebost, Ph.D. - Co-chair of the Sarcoma workshop

Myklebost's research group at Oslo University Hospital - Radium Hospital studies mesenchymal cancer biology. Myklebost acts as the head of the Norwegian Cancer Genomics Consortium, which is a national initiative to bring personalized cancer medicine to clinics.

Nina Aas, M.D., Ph.D. - Co-chair of Palliative Medicine keynote and workshop

Aas is the head of section for palliative medicine in the Department of Oncology at Oslo University Hospital. She is also a professor in palliative medicine at University of Oslo.

Harald Holte, M.D., Ph.D. - Co-chair Lymphoma workshop

Holte is the head of the Lymphoma Program and Lymphoma Research Group at Oslo University Hospital. The majority of his work centers on clinical studies and translational research surrounding lymphomas.

Anne-Lise Børresen-Dale, M.D., Ph.D. - Co-chair of the Personalized Medicine keynote and workshop

Børresen-Dale is a professor at the University of Oslo and is head of a research group in the Department of Genetics at the Institute for Cancer Research, which is a part of Oslo University Hospital - Radium Hospital. Her current research focus is on exploring the systems biology of breast cancer, including molecular genetic studies, radiation sensitivity, tumor aggressiveness and therapy resistance. Børresen-Dale was recently appointed head of the K.G. Jebsen Center for Breast Cancer Research at Oslo University Hospital.

Calendar of Events

Society of Gynecologic Oncology - Annual Meeting
Austin, Texas
March 24-27, 2012

4th Annual Conference of The Indian Society of Neuro-Oncology
Bangalore, India
April 6-8, 2012

GAP Annual Conference
Oslo, Norway
May 14-16, 2012



From April 6-8, 2012, The Indian Society of Neuro-oncology (ISNO) will host its 4th Annual Conference in Bangalore, India. The theme of the meeting will be Molecular Biology and Targeted Therapies in Neuro-oncology. The National Institute of Mental Health and Neurosciences (NIMHANS) hosts the conference, which will include sessions regarding: understanding the biology of malignant gliomas; improving outcomes of infiltrative gliomas; pediatric brain tumors; emerging therapeutic innovations for brain tumors; molecular biology and targeted therapy; management of aggressive meningiomas and cavernous sinus tumors; and management of patients with hereditary brain tumors. Read the complete conference agenda on the website.

Clinica Alemana Neuroncology Course 2012

New Horizons in Gliomas Treatment will be the theme of the IV Course of Neuroncology 2012 hosted by Clinical Alemana in Santiago, Chile from April 12th to 13th. Representing The University of Texas MD Anderson Cancer Center will be Ian E. McCutcheon, M.D., a professor in the Department of Neurosurgery. McCutcheon will provide two talks. One talk will center on micro- and image guided surgery to resection malignant gliomas and the second talk will discuss surgery in eloquent areas of the brain.Clinica Alemana is part of MD Anderson's network of Sister Institutions.

Network News

National Cancer Institute Holds Inaugural Meeting of New Center for Global Health

The new Center for Global Health at NCI held its first meeting last week in Bethesda, MD in order to discuss setting its priorities for global cancer research. Chaired by NCI's director, Harold Varmus, M.D., and the Center's director, Edward Trimble, M.D., the meeting convened over 100 experts in global health to exchange information about their activities provide input on the Center's direction. Alejandro Mohar, M.D., director of Mexico's Instituto Nacional de Cancerología (INCAN), and Rajendra Badwe, M.D.,  director of Tata Memorial Hospital in Mumbai, India, both MD Anderson Sister Institutions, attended. Ernie Hawk, M.D., vice president and division head of Cancer Prevention and Oliver Bogler, Ph.D., vice president of Global Academic Programs, represented MD Anderson. A wide range of government and international agencies also participated in the gathering, including the Center for Disease Control (CDC), the World Health Organization (WHO), the International Agency for Research on Cancer (IARC), the African Organization for Research & Training in Cancer (AORTIC) and the Union for International Cancer Control (UICC). The conversations and presentations during the meeting placed an emphasis on implementation and sustainability of programs and a major theme was prevention in the context of virus-associated cancers. After each session assigned rapporteurs summarized the discussions and proposed actions that could be taken by NCI. The videos for the two-day event are included in the multimedia section below. GAP Connect will highlight any recommendations or report arising from the meeting.

WIN Symposium

Worldwide Innovative Networking (WIN) in personalized cancer medicine will host its 2012 symposium in France from June 28-29. This year's symposium will focus on the efficacy of biomarkers and personalized cancer therapeutics. Although started by two academic institutions, MD Anderson and Institut Gustave Roussy in France, the symposium brings together experts in academia, industry and regulatory to discuss the current state of personalized cancer care. Ultimately, those discussions should lead to collaborative research projects. By accessing local populations the trials can provide a diverse population, which can be an advantage in phase I and II studies. The trials should not exceed three years and are centered on patient needs and improving clinical outcomes and patient quality of life. At this year's symposium, the consortium will be announcing the first four of these collaborative clinical trials. To read more about the symposium, visit the website.